Advanced search
Publication Cover
OncoTargets and Therapy Volume 13, 2020 - Issue
Submit an article Journal homepage
189
Views
22
CrossRef citations to date
0
Altmetric
Review

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer

Wentao Tian1 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha410011, Hunan, People’s Republic of China;2 Xiangya School of Medicine, Central South University, Changsha410013, Hunan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8938-7576
ORCID Icon,
Chenghui Cao1 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha410011, Hunan, People’s Republic of China;2 Xiangya School of Medicine, Central South University, Changsha410013, Hunan, People’s Republic of China
,
Long Shu1 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha410011, Hunan, People’s Republic of China
&
Fang Wu1 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha410011, Hunan, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6627-3437
ORCID Icon
Pages 12113-12129 | Published online: 24 Nov 2020

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Tongtong Sui, Bojun Qiu, Jiaorong Qu, Yuxin Wang, Kunnian Ran, Wei Han & Xiaozhong Peng. (2021) Gambogic amide inhibits angiogenesis by suppressing VEGF/VEGFR2 in endothelial cells in a TrkA-independent manner. Pharmaceutical Biology 59:1, pages 1564-1573.
Read now

Articles from other publishers (21)

Paul Rodrigues, Harun Bangali, Eyhab Ali, Abdreshov Serik Nauryzbaevish, Ahmed Hjazi, Mohammed N. Fenjan, Ahmed Alawadi, Ali Alsaalamy, Mohammed Qasim Alasheqi & Yasser Fakri Mustafa. (2024) The mechanistic role of NAT10 in cancer: Unraveling the enigmatic web of oncogenic signaling. Pathology - Research and Practice 253, pages 154990.
Crossref
Huan Zhu, Hao-Yu Zhao, Cheng Peng, Hong-Zhen Shu, Zhao-Hua Liu, Qin-Mei Zhou & Liang Xiong. (2023) New indolizidine- and pyrrolidine-type alkaloids with anti-angiogenic activities from Anisodus tanguticus. Biomedicine & Pharmacotherapy 167, pages 115481.
Crossref
Linlin Wang, Changqi Du, Bing Jiang, Lin Chen & Zibing Wang. (2023) Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer. Frontiers in Immunology 14.
Crossref
Mahmood Araghi, Reza Mannani, Ali Heidarnejad maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi & Reza Akhavan-Sigari. (2023) Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International 23:1.
Crossref
Yu Zhang, Aleksander S. Popel & Hojjat Bazzazi. (2023) Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. ACS Pharmacology & Translational Science 6:5, pages 710-726.
Crossref
Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, Golgodu Krishnamurthy Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, Kaviyarasi Renu, Saikat Dewanjee, Rupa Sanyal, Abhijit Dey, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Valsala Gopalakrishnan & Alex George. (2023) Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes & Diseases 10:3, pages 960-989.
Crossref
Po-I Liu, Ya-Jing Jiang, An-Chen Chang, Chang-Lun Huang, Yi-Chin Fong, Jeng-Hung Guo, Chun-Lin Liu, Shih-Wei Wang, Ju-Fang Liu, Sunny Li-Yu Chang & Chih-Hsin Tang. (2023) ANGPTL2 promotes VEGF-A synthesis in human lung cancer and facilitates lymphangiogenesis. Aging.
Crossref
Hejing Bao, Ling Zhen Ma, Chengzhu Zhao, Mengge Yu, Baishen Zhang, Juan Zhang, Guibao Peng, Xiaotong Lin, Yinhua Fang, Hehong Bao & Shudong Ma. (2022) Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study. Journal of Cancer Research and Clinical Oncology 149:3, pages 1185-1193.
Crossref
Ji’an Zou, Yue Zeng & Fang Wu. (2023) Opportunities and challenges of neoadjuvant targeted therapy in nonsmall cell lung cancer. Current Opinion in Oncology 35:1, pages 22-30.
Crossref
Tian Wang, Dong Zhang, Chuanlong Guo & Wenyong Zhu. (2022) Novel PARP Inhibitor DDPF-20 Induces DNA Damage and Inhibits Angiogenesis through the PI3K/Akt/VEGF Pathway. Anti-Cancer Agents in Medicinal Chemistry 22:13, pages 2468-2476.
Crossref
Minerva Codruta Badescu, Oana Viola Badulescu, Dragos Viorel Scripcariu, Lăcrămioara Ionela Butnariu, Iris Bararu-Bojan, Diana Popescu, Manuela Ciocoiu, Eusebiu Vlad Gorduza, Irina Iuliana Costache, Elena Rezus & Ciprian Rezus. (2022) Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights. Life 12:7, pages 1034.
Crossref
Fen Wang, Feng Jin, Boran Cheng, Yue Zhang, Qing Zhou & Shubin Wang. (2021) The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 148:7, pages 1721-1735.
Crossref
Hayato Kawachi, Motohiro Tamiya, Kinnosuke Matsumoto, Akihiro Tamiya, Takafumi Yanase, Satoshi Tanizaki & Toru Kumagai. (2022) Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. Investigational New Drugs 40:3, pages 634-642.
Crossref
Chenyang Shi, Jiaxin Li, Guorong Fan & Yu Liu. (2022) Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer. Frontiers in Pharmacology 13.
Crossref
Surui Liu, Jin Yu, Hui Zhang & Jie Liu. (2022) TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Frontiers in Oncology 12.
Crossref
Lingge Yang, Yuan Wu, Huan Xu, Jingnan Zhang, Xinjie Zheng, Long Zhang, Yongfang Wang, Weiyu Chen & Kai Wang. (2022) Identification and Validation of a Novel Six-lncRNA-Based Prognostic Model for Lung Adenocarcinoma. Frontiers in Oncology 11.
Crossref
Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu & Lingling Zhu. (2022) Tumor vessel normalization and immunotherapy in gastric cancer. Therapeutic Advances in Medical Oncology 14, pages 175883592211101.
Crossref
Julian M. Rozenberg, Gleb I. Filkov, Alexander V. Trofimenko, Evgeny A. Karpulevich, Vladimir D. Parshin, Valery V. Royuk, Marina I. Sekacheva & Mikhail O. Durymanov. (2021) Biomedical Applications of Non-Small Cell Lung Cancer Spheroids. Frontiers in Oncology 11.
Crossref
Rui Xu, Xin Luo, Xuan Ye, Huan Li, Hongyue Liu, Qiong Du & Qing Zhai. (2021) SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Fabrizio Fontana & Patrizia Limonta. (2021) Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells 10:5, pages 1133.
Crossref
Evgenya Y. Shabalina, Ekaterina Yu Skorova, D. A. Chudakova, V. B. Anikin, I. V. Reshetov, O. A. Mynbaev & E. V. Petersen. (2021) The matrix-dependent 3D spheroid model of the migration of non-small cell lung cancer: a step towards a rapid automated screening. Frontiers in Molecular Biosciences 8.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.